Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 1, 1996, Pages 7-11

  Williams, Stephen A ^a   Wesnes, Keith ^b   Oliver, Stuart D ^c   Rapeport, William G ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Harvard Medical School   (United Kingdom)

^c Besselaar Clinical Research Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; SERTRALINE;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL;

1-NAPHTHYLAMINE; ADOLESCENT; ADULT; COGNITION; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG SYNERGISM; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; REACTION TIME; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0029878831     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Doogan DP, Caillaid V. Sertraline: a new antidepressant. J Clin Psychiatry 1988;49(8,suppl):46-51
2. Guthrie SK. Sertraline: a new specific serotonin reuptake blocker. DICP Ann Pharmacother 1991;25:952-961
3. Preskorn SH, Burke M. Somatic therapy for major depressive disorder selection of an antidepressant. J Clin Psychiatry 1992;53(9, suppl):5-18
4. Baldessanni RJ. Drugs and the treatment of psychiatric disorders. In: Goodman AG, Rail TW, Nies AS, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: Pergamon Press; 1990:383-435
5. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989;146.399-400
6. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions, I: antidepressants and antipsychotics. J Clin Psychopharmacol 1990; 10:48-50
7. van Harten J, Stevens L, Raghoebar M, et al. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther 1992:52:427-435
8. Wesnes K, Simpson PM, Kidd AG. An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg. Human Psychopharmacology 1988;3:27-43
9. Mattila MJ, Saarialho-Kere U, Mattila M. Acute effects of Sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age J Clin Psychiatry 1988;49(8, suppl):52-58
10. Brickenkamp R. Test d2 Aufmerksamkeits-Belastungs-Test Handanweisung. Gottingen, Germay: Verlag fur Psychologie Dr. C. J. Hogrefe; 1981
11. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211-218
12. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212(suppl):11-19
13. Antelman SM, Kocan D, Edwards DJ, et al. Behavioral effects of a single neuroleptic treatment grow with the passage of time. Brain Res 1986:385: 58-67
14. Preskorn S, Lane R. 50 mg/day as the optimum dose for sertraline. Int Clin Psychopharmacol. In press
15. Saletu B, Grünberger J. Drug profiling by computed electroencephalography and brain maps, with special consideration of sertralme and its psychometric effects. J Clin Psychiatry 1988:49(8, suppl):59-71
16. Hindmarch I. Bhatti JZ. Psychopharmacological effects of sertraline in normal, healthy volunteers, Eur J Clin Pharmacol 1988:35:221-223
17. Hindmarch I. The effects of sertraline on psychomotor performance in elderly volunteers. J Clin Psychiatry 1990:51(12, suppl B):34-36
18. Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 1994;9(suppl 3):13-19
19. Sindrup SH, Brøsen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-287
20. Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-409
21. Gram LF, Debruyne D, Caillard V, et al. Substantial rise in sparteine metabolic ratio during haloperidol treatment Br J Clin Pharmacol 1989;27: 272-275
22. Brøsen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-239
23. von Moltke LL, Greenblatt DJ. Cotreau-Bibbo MM, et al. Inhibition of desipramine hydroxyiation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazoîe: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268: 1278-1283
24. Alderman J, Greenblatt DJ, Allison J, et al. Desipramine pharmacokinetics with the serotonin reuptake inhibitors (SSRIs), paroxetine or sertraline. Presented at the 19th Collegium Internationale Neuro-Psychopharmacologicum; June 27-July 1,1994; Washington, DC
25. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-98
26. Brøsen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-355
27. Lee MS, You YW, Kim SH. Co-administration of sertraline and haloperidol. Presented at the 19th Collegium Internationale Neuro-Psychopharmacologicum; June 27-July 1, 1994; Washington, DC